| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 582.6 | 432.3 | 563.8 |
| Other income | 8.1 | 0.4 | 0.9 |
| Total income | 590.7 | 432.7 | 564.6 |
| Profit before exceptional items & tax | 76.2 | 59.5 | 114.6 |
| Exceptional items | 0.0 | 2.8 | 0.0 |
| Profit before tax | 81.7 | 61.6 | 114.6 |
| Net profit | 61.1 | 47.0 | 88.3 |
| Operating margin | 13.8% | 14.2% | 20.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -30.80% |
|---|---|
| Net profit, quarter on quarter | +30.00% |
| Revenue, year on year | +3.30% |
NSE results filing, NSE: AARTIPHARM. Figures extracted from the filing.
Aarti Pharmalabs Ltd: key numbers
- Share price
- ₹939.55
- Market cap
- ₹8,520 Cr
- Revenue (annual)
- ₹1,819 Cr
- Net profit (annual)
- ₹174.7 Cr
- P/E (TTM)
- 40.0×Sector 50.4×
- Promoter holding
- 42.86%-0.22% QoQ
- FII holding
- 8.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Pharmalabs Ltd
All →Aarti Pharmalabs Promoter Selling: ₹106.4 Cr
Promoters sold a total of 15.12 lakh shares via open market transactions, aggregating to ₹106.43 Crore.
- Value
- ₹106.4 Cr
Aarti Pharmalabs Management Change
Aarti Pharmalabs reported directorate changes, including Shri Rashesh Gogri's appointment as Managing Director, Smt. Hetal Gogri Gala's re-designation, and the cessation of Shri Rajendra Gogri.
Aarti Pharmalabs Promoter Selling
Aarti Pharmalabs promoters sold a net 29.03 lakh shares, reducing their stake from 42.88% to 39.66%. No transaction value is disclosed in this periodic SAST filing.
Aarti Pharmalabs Investor Presentation: Key Takeaways
7th AGM presentation for Aarti Pharmalabs. Reported Standalone FY26 Revenue of INR 1,798 Cr with 23% EBITDA margin; Consolidated revenue down 14% YoY to INR 1,819 Cr.
- Call
- Guides 18% growth
Aarti Pharmalabs Annual General Meeting
Aarti Pharmalabs conducted its 7th Annual General Meeting on September 22, 2026, to transact ordinary and special business, with voting results to follow.
Aarti Pharmalabs Promoter Selling: ₹10.43 Cr
Promoter Group entities, Safechem Enterprises and Relacion Trusteeship, sold 1,19,400 shares of Aarti Pharmalabs in the open market for a total of ₹10.43 Crore.
- Value
- ₹10.43 Cr